Drug intelligence / Profile preview

MK-6916

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral (planned For Clinical Trials)[2]

Overview

MK-6916 is an investigational drug being developed by Merck Sharp & Dohme (Merck & Co) as a new molecular entity. As of March 2025, it is in preclinical development with plans for a phase 1 trial in healthy volunteers. The specific mechanism of action and therapeutic indication have not been disclosed publicly. There are no known brand names, approved indications, or reported adverse events associated with this compound at this time[2][3][9].

Beyond the preview

Go deeper on MK-6916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-6916.

Explore the full profile